Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges

Clinical Trials

Volumn 13, Issue 1, 2016, Pages 49-56

  Kennedy, Stephen B ^a,b   Neaton, James D ^c   Lane, H Clifford ^d   Kieh, Mark W S ^a   Massaquoi, Moses B F ^a   Touchette, Nancy A ^d   Nason, Martha C ^d   Follmann, Dean A ^d   Boley, Fatorma K ^a,e   Johnson, Melvin P ^a   Larson, Gregg ^c   Kateh, Francis N ^b,f   Nyenswah, Tolbert G ^b,f  

^a Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)   (Liberia)

^b Emergency Operations Center EoC   (Liberia)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Liberian Institute for Biomedical Research (LIBR)   (Liberia)

^f Ministry of Health (MoH)   (Liberia)

Author keywords

clinical trials; Ebola virus disease; emerging and re emerging infections; epidemics; infectious diseases; Liberia; partnership; social mobilization

Indexed keywords

EBOLA VACCINE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INTENTION TO TREAT ANALYSIS; LIBERIA; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT OUTCOME; VACCINATION; CLINICAL PROTOCOL; HEMORRHAGIC FEVER, EBOLA; INTERNATIONAL COOPERATION; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; UNITED STATES; WORLD HEALTH ORGANIZATION;

CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; EBOLA VACCINES; FOLLOW-UP STUDIES; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTERNATIONAL COOPERATION; LIBERIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84957606591     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515621037     Document Type: Article

References (12)

1. World Health Organization. Global alert & response: Ebola virus disease (EVD)., 2014, http://www.who.int/csr/don/2014-03-30-ebola-lbr/en/
2. World Health Organization. The Ebola outbreak in Liberia is over., http://www.who.int/mediacentre/news/statements/2015/liberia-ends-ebola/en/ (2015,. accessed 11 November 2015).
3. World Health Organization. Ebola transmission in Liberia over. Nation enters 90-day intensive surveillance period, http://www.who.int/mediacentre/news/statements/2015/ebola-transmission-over-liberia/en/ (2015,. accessed 11 November 2015).
4. World Health Organization. Ebola situation report., 16 2015, http://apps.who.int/ebola/current-situation/ebola-situation-report-16-september-2015 (. accessed 11 November 2015).
5. Buseh AG, Stevens PE, Bromberg M, et al. The Ebola epidemic in West Africa: challenges, opportunities, and policy priority areas. Nurs Outlook 2015; 63: 30-40.
6. Siedner MJ, Gostin LO, Cranmer HH, et al. Strengthening the detection of and response to public health emergencies: lessons from the West African Ebola epidemic. PLoS Med 2015; 12: e1001804.
7. Gostin LO, Friedman EA., A retrospective and prospective analysis of the West African Ebola virus disease epidemic: Robust national health systems at the foundation and an empowered WHO at the apex. Lancet 2015; 385: 1902-1909.
8. Kennedy SB, Nisbett RA., The Ebola epidemic: a transformative moment for global health. Bull World Health Organ 2015; 93: 2.
9. Agnandji ST, Huttner A, Zinser ME, et al. Phase I trials of rVSV Ebola vaccine in Africa and Europe: preliminary report. N Engl J Med. Epub ahead of print 1 2015. DOI: 10.1056/NEJMoa1502924.
10. Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1B, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015; 385: 1545-1554.
11. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med. Epub ahead of print 26 2014. DOI: 10.1056/NEJMoa1410863.
12. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge. Nat Med 2014; 20: 1126-1129.